



## Clinical trial results:

### A Phase II, Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of GSK1120212 Compared with Docetaxel in 2nd Line Subjects with Targeted Mutations (KRAS, NRAS, BRAF, MEK1) in Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC Stage IIIBwet-IV).

#### Summary

EudraCT number	2011-000634-11
Trial protocol	GR ES NL IT HU
Global end of trial date	24 September 2013

#### Results information

Result version number	v1
This version publication date	07 March 2016
First version publication date	10 July 2015

#### Trial information

##### Trial identification

Sponsor protocol code	MEK114653
-----------------------	-----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 866-435-7343,

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	24 September 2013
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	24 September 2013
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

To compare Progression-Free Survival (PFS) in KRAS mutated NSCLC subjects who are receiving GSK1120212 with those receiving docetaxel.

Protection of trial subjects:

Per protocol, trial subjects received full supportive care during the study including transfusions of blood and blood products, and treatment with antibiotics, anti-emetics, anti-diarrheals, and analgesics, and other care as deemed appropriate, and in accordance with their institutional guidelines.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 September 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 21
Country: Number of subjects enrolled	Spain: 6
Country: Number of subjects enrolled	France: 28
Country: Number of subjects enrolled	Greece: 3
Country: Number of subjects enrolled	Hungary: 8
Country: Number of subjects enrolled	Italy: 10
Country: Number of subjects enrolled	Korea, Republic of: 21
Country: Number of subjects enrolled	United States: 37
Worldwide total number of subjects	134
EEA total number of subjects	76

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0

Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	81
From 65 to 84 years	53
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Participants (par.) who met eligibility criteria at Screening were then randomized to the treatment period. A total of 134 participants were randomized, and 130 participants entered the treatment period.

### Pre-assignment

Screening details:

In the Randomized Phase (RP), participants were treated until disease progression (PD), death, or unacceptable adverse events were experienced. After PD in the RP, participants were given the option of crossing over to the alternative treatment arm in a Cross-over Phase (CP). Milestone of Completed = Par. with PD including death due to PD.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	GSK1120212 2 mg in RP

Arm description:

Participants received GSK1120212 2 milligrams (mg) orally once daily continuously in the Randomized Phase (RP). Participants continued treatment until disease progression, death, or unacceptable adverse events were experienced. Participants who experienced disease progression in the RP were given the option of crossing over to the alternative treatment arm (docetaxel 75 milligrams per meters squared [mg/m<sup>2</sup>]), and continuing in the Cross-over Phase (CP).

Arm type	Experimental
Investigational medicinal product name	trametinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

2 mg once daily dosing

<b>Arm title</b>	Docetaxel 75 mg/m <sup>2</sup> in RP
------------------	--------------------------------------

Arm description:

Participants received docetaxel 75 mg per meters squared (m<sup>2</sup>) intravenously (IV) every 3 weeks in the RP. Participants continued treatment on a 21-day cycle until disease progression, death, or unacceptable adverse events were experienced. Participants who experienced disease progression in the RP were given the option of crossing over to the alternative treatment arm (GSK1120212 2 mg), and continuing in the CP.

Arm type	Active comparator
Investigational medicinal product name	docetaxel
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for infusion
Routes of administration	Intravenous use

Dosage and administration details:

75 mg/m<sup>2</sup> once every three weeks

<b>Number of subjects in period 1</b>	<b>GSK1120212 2 mg in RP</b>	<b>Docetaxel 75 mg/m<sup>2</sup> in RP</b>
Started	89	45
Crossover Started	23	2
Crossover Completed	0	0
Completed	0	0
Not completed	89	45
Consent withdrawn by subject	2	1
Physician decision	1	9
Did not take study drug	2	2
Adverse event, non-fatal	20	4
'PD including Death due to PD '	56	28
Study Closed/Terminated	8	1

## Baseline characteristics

### Reporting groups

Reporting group title	GSK1120212 2 mg in RP
-----------------------	-----------------------

Reporting group description:

Participants received GSK1120212 2 milligrams (mg) orally once daily continuously in the Randomized Phase (RP). Participants continued treatment until disease progression, death, or unacceptable adverse events were experienced. Participants who experienced disease progression in the RP were given the option of crossing over to the alternative treatment arm (docetaxel 75 milligrams per meters squared [mg/m<sup>2</sup>]), and continuing in the Cross-over Phase (CP).

Reporting group title	Docetaxel 75 mg/m <sup>2</sup> in RP
-----------------------	--------------------------------------

Reporting group description:

Participants received docetaxel 75 mg per meters squared (m<sup>2</sup>) intravenously (IV) every 3 weeks in the RP. Participants continued treatment on a 21-day cycle until disease progression, death, or unacceptable adverse events were experienced. Participants who experienced disease progression in the RP were given the option of crossing over to the alternative treatment arm (GSK1120212 2 mg), and continuing in the CP.

Reporting group values	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP	Total
Number of subjects	89	45	134
Age categorical			
Units: Subjects			

Age continuous			
test			
Units: years			
arithmetic mean	61.4	60.9	
standard deviation	± 8.97	± 10.06	-
Gender categorical			
Units: Subjects			
Female	43	22	65
Male	46	23	69
Race			
Units: Subjects			
White - White/Caucasian/European Heritage	73	32	105
Asian - East Asian Heritage	11	9	20
White - Arabic/North African Heritage	1	3	4
African American/African Heritage	3	0	3
Asian - South East Asian Heritage	0	1	1
Missing	1	0	1

## End points

### End points reporting groups

Reporting group title	GSK1120212 2 mg in RP
-----------------------	-----------------------

#### Reporting group description:

Participants received GSK1120212 2 milligrams (mg) orally once daily continuously in the Randomized Phase (RP). Participants continued treatment until disease progression, death, or unacceptable adverse events were experienced. Participants who experienced disease progression in the RP were given the option of crossing over to the alternative treatment arm (docetaxel 75 milligrams per meters squared [mg/m<sup>2</sup>]), and continuing in the Cross-over Phase (CP).

Reporting group title	Docetaxel 75 mg/m <sup>2</sup> in RP
-----------------------	--------------------------------------

#### Reporting group description:

Participants received docetaxel 75 mg per meters squared (m<sup>2</sup>) intravenously (IV) every 3 weeks in the RP. Participants continued treatment on a 21-day cycle until disease progression, death, or unacceptable adverse events were experienced. Participants who experienced disease progression in the RP were given the option of crossing over to the alternative treatment arm (GSK1120212 2 mg), and continuing in the CP.

Subject analysis set title	GSK1120212 2 mg in CP
----------------------------	-----------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

#### Subject analysis set description:

Participants received GSK1120212 2 milligrams (mg) orally once daily continuously in the Randomized Phase (RP). Participants continued treatment until disease progression, death, or unacceptable adverse events were experienced. Participants who experienced disease progression in the RP were given the option of crossing over to the alternative treatment arm (docetaxel 75 milligrams per meters squared [mg/m<sup>2</sup>]), and continuing in the Cross-over Phase (CP).

Subject analysis set title	Docetaxel 75 mg/m <sup>2</sup> in CP
----------------------------	--------------------------------------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

#### Subject analysis set description:

Participants received docetaxel 75 mg per meters squared (m<sup>2</sup>) intravenously (IV) every 3 weeks in the RP. Participants continued treatment on a 21-day cycle until disease progression, death, or unacceptable adverse events were experienced. Participants who experienced disease progression in the RP were given the option of crossing over to the alternative treatment arm (GSK1120212 2 mg), and continuing in the CP.

### Primary: Progression-Free Survival (PFS) as assessed by the investigator (INV)

End point title	Progression-Free Survival (PFS) as assessed by the investigator (INV)
-----------------	---

#### End point description:

PFS is defined as the time from RAN until the earliest date of documented radiological PD or DT due to any cause. PD was assessed by the INV according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. PD is defined as at least a 20% increase in the sum of the diameters (SD) of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation. For participants who did not have a documented date of PD or DT, PFS was censored at the date of the last adequate assessment. For participants who received subsequent anti-cancer therapy prior to the date of documented PD or DT, PFS was censored at the date of the last adequate assessment prior to the initiation of therapy.

End point type	Primary
----------------	---------

#### End point timeframe:

From randomization (RAN) until the earliest date of documented radiological disease progression (PD) or death (DT) due to any cause (maximum of 10.2 months)

<b>End point values</b>	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	86 <sup>[1]</sup>	43 <sup>[2]</sup>		
Units: Weeks				
median (confidence interval 95%)	11.7 (7 to 12.4)	11.4 (6.1 to 18.3)		

Notes:

[1] - Modified Intent-to-Treat (MITT) Population: all randomized participants with KRAS mutation-positive.

[2] - Modified Intent-to-Treat (MITT) Population: all randomized participants with KRAS mutation-positive.

### Statistical analyses

<b>Statistical analysis title</b>	Analysis 1
Comparison groups	Docetaxel 75 mg/m <sup>2</sup> in RP v GSK1120212 2 mg in RP
Number of subjects included in analysis	129
Analysis specification	Pre-specified
Analysis type	superiority <sup>[3]</sup>
P-value	= 0.5197 <sup>[4]</sup>
Method	Logrank
Parameter estimate	Hazard ratio (HR)
Point estimate	1.14
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.75
upper limit	1.75

Notes:

[3] - HRs were estimated using a Pike estimator. The HR from the stratified log-rank test was adjusted for gender (male versus female).

[4] - P-value from the stratified log-rank was adjusted for gender (male versus female).

### Secondary: Number of participants with the indicated worst-case on-therapy change from Baseline in the indicated clinical chemistry parameters: Randomized Phase

End point title	Number of participants with the indicated worst-case on-therapy change from Baseline in the indicated clinical chemistry parameters: Randomized Phase
-----------------	---

End point description:

Parameters summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade (G) 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to any G, G3, or G4 occurred. Parameters included: albumin, alkaline phosphatase (ALKP), alanine amino transferase (ALT), aspartate amino transferase (AST), total bilirubin, calcium (hypercalcemia), calcium (hypocalcemia), creatine kinase, creatinine, glucose (hyperglycemia), glucose (hypoglycemia), potassium (hyperkalemia), potassium (hypokalemia), sodium (hypernatremia), and sodium (hyponatremia). Worst-case on-therapy (OT) change from BL were summarized. Worst-case OT was defined using the on-therapy window and changes were identified using both scheduled and unscheduled assessments. Only par. with data available at specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (BL); Days 1, 8, and 15 of Cycle 1; and Day 1 of every cycle thereafter until treatment discontinuation of the Randomized Phase (up to Study Week 40)



End point values	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 <sup>[5]</sup>	43 <sup>[6]</sup>		
Units: Participants				
Albumin, Increase to any G (IAG), n=86, 43	57	21		
Albumin, Increase to G3, n=86, 43	4	1		
Albumin, Increase to G4, n=86, 43	0	0		
ALKP, IAG, n=85, 43	26	3		
ALKP, Increase to G3, n =85, 43	2	1		
ALKP, Increase to G4, n=85, 43	0	0		
ALT, IAG, n=87, 43	32	7		
ALT, Increase to G3, n=87, 43	3	1		
ALT, Increase to G4, n=87, 43	0	0		
AST, IAG, n=86, 43	55	11		
AST, Increase to G3, n=86, 43	1	0		
AST, Increase to G4, n=86, 43	0	0		
Total bilirubin, IAG, n=85, 42	3	3		
Total bilirubin, Increase to G3, n=85, 42	0	0		
Total bilirubin, Increase to G4, n=85, 42	0	0		
Calcium (hypercalcemia), IAG, n =87, 43	9	3		
Calcium (hypercalcemia), Increase to G3, n=87, 43	0	0		
Calcium (hypercalcemia), Increase to G4, n=87, 43	0	0		
Calcium (hypocalcemia), IAG, n=87, 43	4	1		
Calcium (hypocalcemia), Increase to G3, n=87, 43	0	1		
Calcium (hypocalcemia), Increase to G4, n=87, 43	1	0		
Creatine kinase, IAG, n=1, 0	0	0		
Creatine kinase, Increase to G3, n=1, 0	0	0		
Creatine kinase, Increase to G4, n=1, 0	0	0		
Creatinine, IAG, n=87, 43	12	6		
Creatinine, Increase to G3, n=87, 43	3	1		
Creatinine, Increase to G4, n=87, 43	0	0		
Glucose (hyperglycemia), IAG, n=87, 43	47	24		
Glucose (hyperglycemia), Increase to G3, n=87, 43	5	2		
Glucose (hyperglycemia), Increase to G4, n=87, 43	0	0		
Glucose (hypoglycemia), IAG, n=87, 43	4	4		
Glucose (hypoglycemia), Increase to G3, n=87, 43	0	0		
Glucose (hypoglycemia), Increase to G4, n=87, 43	0	0		
Potassium (hyperkalemia), IAG, n=86, 43	9	4		
Potassium (hyperkalemia), Increase to G3, n=86, 43	1	1		
Potassium (hyperkalemia), Increase to G4n=86, 43	0	0		
Potassium (hypokalemia), IAG, n=86, 43	8	2		

Potassium (hypokalemia), Increase to G3, n=86, 43	0	0		
Potassium (hypokalemia), Increase to G4, n=86, 43	0	0		
Sodium (hypernatremia), IAG, n=87, 43	12	2		
Sodium (hypernatremia), Increase to G3, n=87, 43	0	0		
Sodium (hypernatremia), Increase to G4, n=87, 43	0	0		
Sodium (hyponatremia), IAG, n=87, 43	16	5		
Sodium (hyponatremia), Increase to G3, n=87, 43	2	1		
Sodium (hyponatremia), Increase to G4, n=87, 43	0	0		

Notes:

[5] - Safety Population: all participants that received at least one dose of study treatment.

[6] - Safety Population: all participants that received at least one dose of study treatment.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with the indicated worst-case on-therapy change from Baseline in the indicated clinical chemistry parameters: Crossover Phase

End point title	Number of participants with the indicated worst-case on-therapy change from Baseline in the indicated clinical chemistry parameters: Crossover Phase
-----------------	--

End point description:

Clinical chemistry parameters were summarized according to NCI CTCAE grade, version 4.0. Grade (G) 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to any grade, Grade 3, or Grade 4 occurred. Clinical chemistry parameters included: albumin, alkaline phosphatase (ALKP), alanine amino transferase (ALT), aspartate amino transferase (AST), total bilirubin, calcium (hypercalcemia), calcium (hypocalcemia), creatine kinase, creatinine, glucose (hyperglycemia), glucose (hypoglycemia), potassium (hyperkalemia), potassium (hypokalemia), sodium (hypernatremia), and sodium (hyponatremia). Worst-case on-therapy changes from Baseline were summarized. Worst-case on-therapy was defined using the on-therapy window and changes were identified using both scheduled and unscheduled assessments. Only participants with data available at the specified time points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; Days 1, 8, and 15 of Cycle 1; and Day 1 of every cycle thereafter until treatment discontinuation of the Crossover Phase (up to Study Week 19)

End point values	GSK1120212 2 mg in CP	Docetaxel 75 mg/m <sup>2</sup> in CP		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	23 <sup>[7]</sup>	1 <sup>[8]</sup>		
Units: Participants				
Albumin, Increase to any G (IAG), n=23, 1	15	1		
Albumin, Increase to G3, n=23, 1	4	0		
Albumin, Increase to G4, n=23, 1	0	0		
ALKP, IAG, n=23, 1	10	0		
ALKP, Increase to G3, n =23, 1	1	0		
ALKP, Increase to G4, n=23, 1	0	0		

ALT, IAG, n=23, 1	7	0		
ALT, Increase to G3, n=23, 1	1	0		
ALT, Increase to G4, n=23, 1	0	0		
AST, IAG, n=23, 1	9	0		
AST, Increase to G3, n=23, 1	1	0		
AST, Increase to G4, n=23, 1	0	0		
Total bilirubin, IAG, n=22, 1	1	0		
Total bilirubin, Increase to G3, n=22, 1	0	0		
Total bilirubin, Increase to G4, n=22, 1	0	0		
Calcium (hypercalcemia), IAG, n =23, 1	1	0		
Calcium (hypercalcemia), Increase to G3, n=23, 1	0	0		
Calcium (hypercalcemia), Increase to G4, n=23, 1	0	0		
Calcium (hypocalcemia), IAG, n=23, 1	0	0		
Calcium (hypocalcemia), Increase to G3, n=23, 1	0	0		
Calcium (hypocalcemia), Increase to G4, n=23, 1	0	0		
Creatine kinase, IAG, n=1, 0	1	0		
Creatine kinase, Increase to G3, n=1, 0	0	0		
Creatine kinase, Increase to G4, n=1, 0	0	0		
Creatinine, IAG, n=23, 1	3	0		
Creatinine, Increase to G3, n=23, 1	0	0		
Creatinine, Increase to G4, n=23, 1	0	0		
Glucose (hyperglycemia), IAG, n=23, 1	10	0		
Glucose (hyperglycemia), Increase to G3, n=23, 1	0	0		
Glucose (hyperglycemia), Increase to G4, n=23, 1	0	0		
Glucose (hypoglycemia), IAG, n=23, 1	1	0		
Glucose (hypoglycemia), Increase to G3, n=23, 1	0	0		
Glucose (hypoglycemia), Increase to G4, n=23, 1	0	0		
Potassium (hyperkalemia), IAG, n=23, 1	3	0		
Potassium (hyperkalemia), Increase to G3, n=23, 1	1	0		
Potassium (hyperkalemia), Increase to G4, n=23, 1	0	0		
Potassium (hypokalemia), IAG, n=23, 1	1	0		
Potassium (hypokalemia), Increase to G3, n=23, 1	0	0		
Potassium (hypokalemia), Increase to G4, n=23, 1	0	0		
Sodium (hypernatremia), IAG, n=23, 1	1	0		
Sodium (hypernatremia), Increase to G3, n=23, 1	0	0		
Sodium (hypernatremia), Increase to G4, n=23, 1	0	0		
Sodium (hyponatremia), IAG, n=23, 1	3	0		
Sodium (hyponatremia), Increase to G3, n=23, 1	2	0		
Sodium (hyponatremia), Increase to G4, n=23, 1	0	0		

Notes:

[7] - Crossover Population: par. who, at the point of PD during RP, elected to enter the CP of the study.

[8] - Crossover Population: par. who, at the point of PD during RP, elected to enter the CP of the study.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with the indicated worst-case on-therapy change from Baseline in the indicated hematology parameters: Randomized Phase

End point title	Number of participants with the indicated worst-case on-therapy change from Baseline in the indicated hematology parameters: Randomized Phase
-----------------	---

End point description:

Hematology parameters were summarized according to NCI CTCAE grade, version 4.0. Grade (G) 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to any G (IAG), G3, or G4 occurred. Hematology parameters included: haemoglobin (increased [inc]), haemoglobin (anemia), lymphocyte count (ct) (inc), lymphocyte ct (decreased [dec]), total absolute neutrophil count (ANC), platelet ct, and white blood cell count (WBC). Worst-case on-therapy changes from Baseline were summarized. Worst-case on-therapy was defined using the on-therapy window and changes were identified using both scheduled and unscheduled assessments.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; Days 1, 8, and 15 of Cycle 1; and Day 1 of every cycle thereafter until treatment discontinuation of the Randomized Phase (up to Study Week 40)

End point values	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 <sup>[9]</sup>	43 <sup>[10]</sup>		
Units: Participants				
Haemoglobin (inc), IAG, n=87, 43	0	0		
Haemoglobin (inc), Increase to G3, n=87, 43	0	0		
Haemoglobin (inc), Increase to G4, n=87, 43	0	0		
Haemoglobin (anemia), IAG, n=86, 43	34	27		
Haemoglobin (anemia), Increase to G3, n=86, 43	8	3		
Haemoglobin (anemia), Increase to G4, n=86, 43	0	0		
Lymphocyte ct (inc), IAG, n=86, 43	9	2		
Lymphocyte ct (inc), Increase to G3, n=86, 43	1	0		
Lymphocyte ct (inc), Increase to G4, n=86, 43	0	0		
Lymphocyte ct (dec), IAG, n=85, 43	18	19		
Lymphocyte ct (dec), Increase to G3, n=85, 43	4	2		
Lymphocyte ct (dec), Increase to G4, n=85, 43	0	0		

ANC, IAG, n=86, 43	5	34		
ANC, Increase to G3, n=86, 43	0	13		
ANC, Increase to G4, n=86, 43	0	13		
Platelet ct, IAG, n=87, 43	15	3		
Platelet ct, Increase to G3, n=87, 43	0	0		
Platelet ct, Increase to G4, n=87, 43	0	0		
WBC, IAG, n=87, 43	5	33		
WBC, Increase to G3, n=87, 43	0	17		
WBC, Increase to G4, n=87, 43	1	0		

Notes:

[9] - Safety Population. Only participants with data available at the specified time points were analyzed.

[10] - Safety Population. Only participants with data available at the specified time points were analyzed.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with the indicated worst-case on-therapy change from Baseline in the indicated hematology parameters: Crossover Phase

End point title	Number of participants with the indicated worst-case on-therapy change from Baseline in the indicated hematology parameters: Crossover Phase
-----------------	--

End point description:

Hematology parameters were summarized according to NCI CTCAE grade, version 4.0. Grade (G) 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to any G (IAG), G3, or G4 occurred. Hematology parameters included: haemoglobin (increased [inc]), haemoglobin (anemia), lymphocyte count (ct) (inc), lymphocyte ct (decreased [dec]), total absolute neutrophil count (ANC), platelet ct, and white blood cell count (WBC). Worst-case on-therapy changes from Baseline were summarized. Worst-case on-therapy was defined using the on-therapy window and changes were identified using both scheduled and unscheduled assessments.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; Days 1, 8, and 15 of Cycle 1; and Day 1 of every cycle thereafter until treatment discontinuation of the Crossover Phase (up to Study Week 19)

End point values	GSK1120212 2 mg in CP	Docetaxel 75 mg/m <sup>2</sup> in CP		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	23 <sup>[11]</sup>	1 <sup>[12]</sup>		
Units: Participants				
Haemoglobin (inc), IAG, n=23, 1	0	0		
Haemoglobin (inc), Increase to G3, n=23, 1	0	0		
Haemoglobin (inc), Increase to G4, n=23, 1	0	0		
Haemoglobin (anemia), IAG, n=23, 1	12	0		
Haemoglobin (anemia), Increase to G3, n=23, 1	2	0		
Haemoglobin (anemia), Increase to G4, n=23, 1	0	0		
Lymphocyte ct (inc), IAG, n=23, 1	1	0		

Lymphocyte ct (inc), Increase to G3, n=23, 1	0	0		
Lymphocyte ct (inc), Increase to G4, n=23, 1	0	0		
Lymphocyte ct (dec), IAG, n=23, 1	3	0		
Lymphocyte ct (dec), Increase to G3, n=23, 1	0	0		
Lymphocyte ct (dec), Increase to G4, n=23, 1	0	0		
ANC, IAG, n=19, 0	0	0		
ANC, Increase to G3, n=19, 0	0	0		
ANC, Increase to G4, n=19, 0	0	0		
Platelet ct, IAG, n=23, 1	4	0		
Platelet ct, Increase to G3, n=23, 1	0	0		
Platelet ct, Increase to G4, n=23, 1	0	0		
WBC, IAG, n=23, 1	0	0		
WBC, Increase to G3, n=23, 1	0	0		
WBC, Increase to G4, n=23, 1	0	0		

Notes:

[11] - Crossover Population. Only par. with data available at the specified time points were analyzed.

[12] - Crossover Population. Only par. with data available at the specified time points were analyzed.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with the indicated worst-case on-therapy change from Baseline with respect to normal ranges in the indicated clinical chemistry parameters: Randomized Phase

End point title	Number of participants with the indicated worst-case on-therapy change from Baseline with respect to normal ranges in the indicated clinical chemistry parameters: Randomized Phase
-----------------	---

End point description:

Data are presented for only those clinical chemistry parameters for which the following worst-case on-therapy changes from Baseline with respect to the normal range were observed: decrease to low, change to normal (CTN) or no change, or increase to high. Clinical chemistry parameters included: lactate dehydrogenase, total protein, and urea/blood urea nitrogen (BUN). Worst-case on-therapy changes from Baseline were summarized. Worst-case on-therapy was defined using the on-therapy window and changes were identified using both scheduled and unscheduled assessments. Normal ranges for each parameter may vary depending on the laboratory (central versus local) and the participant (age, gender, etc.).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; Days 1, 8, and 15 of Cycle 1; and Day 1 of every cycle thereafter until treatment discontinuation of the Randomized Phase (up to Study Week 40)

End point values	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 <sup>[13]</sup>	43 <sup>[14]</sup>		
Units: Participants				
Lactate dehydrogenase, Decrease to low, n=87, 43	1	0		
Lactate dehydrogenase, CTN or no change, n=87, 43	40	23		

Lactate dehydrogenase, Increase to high, n=87, 43	46	20		
Total Protein, Decrease to low, n=86, 43	31	12		
Total Protein, CTN or no change, n=86, 43	55	31		
Total Protein, Increase to high, n=86, 43	1	0		
Urea/BUN, Decrease to low, n=87, 43	0	0		
Urea/BUN, CTN or no change, n=87, 43	62	34		
Urea/BUN, Increase to high, n=87,43	25	9		

Notes:

[13] - Safety Population. Only participants with data available at the specified time points were analyzed.

[14] - Safety Population. Only participants with data available at the specified time points were analyzed.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with the indicated worst-case on-therapy change from Baseline with respect to normal ranges in the indicated clinical chemistry parameters: Crossover Phase

End point title	Number of participants with the indicated worst-case on-therapy change from Baseline with respect to normal ranges in the indicated clinical chemistry parameters: Crossover Phase
-----------------	--

End point description:

Data are presented for only those clinical chemistry parameters for which the following worst-case on-therapy changes from Baseline with respect to the normal range were observed: decrease to low, change to normal (CTN) or no change, or increase to high. Clinical chemistry parameters included: lactate dehydrogenase, total protein, and urea/blood urea nitrogen (BUN). Worst-case on-therapy changes from Baseline were summarized. Worst-case on-therapy was defined using the on-therapy window and changes were identified using both scheduled and unscheduled assessments. Normal ranges for each parameter may vary depending on the laboratory (central versus local) and the participant (age, gender, etc.).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; Days 1, 8, and 15 of Cycle 1; and Day 1 of every cycle thereafter until treatment discontinuation of the Crossover Phase (up to Study Week 19)

End point values	GSK1120212 2 mg in CP	Docetaxel 75 mg/m <sup>2</sup> in CP		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	23 <sup>[15]</sup>	1 <sup>[16]</sup>		
Units: Participants				
Lactate dehydrogenase, Decrease to low	0	0		
Lactate dehydrogenase, CTN or no change	15	1		
Lactate dehydrogenase, Increase to high	8	0		
Total Protein, Decrease to low	15	0		
Total Protein, CTN or no change	8	1		
Total Protein, Increase to high	0	0		
Urea/BUN, Decrease to low	0	0		
Urea/BUN, CTN or no change	18	1		

Urea/BUN, Increase to high	5	0		
----------------------------	---	---	--	--

Notes:

[15] - Crossover Population. Only par. with data available at the specified time points were analyzed.

[16] - Crossover Population. Only par. with data available at the specified time points were analyzed.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with the indicated worst-case on-therapy change from Baseline with respect to normal ranges in the indicated hematology parameters: Randomized Phase

End point title	Number of participants with the indicated worst-case on-therapy change from Baseline with respect to normal ranges in the indicated hematology parameters: Randomized Phase
-----------------	---

End point description:

Data are presented for only those hematology parameters for which the following worst-case on-therapy changes from Baseline with respect to the normal range were observed: decrease to low, change to normal (CTN) or no change, or increase to high. Hematology parameters included: atypical lymphs, atypical lymphs (percentage [%]), basophils, eosinophils, metamyelocytes, monocytes, myelocytes, neutrophil bands (%). Worst-case on-therapy changes from Baseline were summarized. Worst-case on-therapy was defined using the on-therapy window and changes were identified using both scheduled and unscheduled assessments. Normal ranges for each parameter may vary depending on the laboratory (central versus local) and the participant (age, gender, etc.).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; Days 1, 8, and 15 of Cycle 1; and Day 1 of every cycle thereafter until treatment discontinuation of the Randomized Phase (up to Study Week 40)

End point values	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	86 <sup>[17]</sup>	43 <sup>[18]</sup>		
Units: Participants				
Atypical lymphs, Decrease to low, n=0, 3	0	0		
Atypical lymphs, CTN or no change, n=0, 3	0	0		
Atypical lymphs, Increase to high, n=0, 3	0	3		
Atypical lymphs (%), Decrease to low, n=0, 3	0	0		
Atypical lymphs (%), CTN or no change, n=0, 3	0	0		
Atypical lymphs (%), Increase to high, n=0, 3	0	3		
Basophils, Decrease to low, n=86, 43	0	0		
Basophils, CTN or no change, n=86, 43	82	41		
Basophils, Increase to high, n=86, 43	4	2		
Eosinophils, Decrease to low, n=86, 43	1	1		
Eosinophils, CTN or no change, n=86, 43	77	42		
Eosinophils, Increase to high, n=86, 43	9	0		



Metamyelocytes, Decrease to low, n=1, 7	0	0		
Metamyelocytes, CTN or no change, n=1, 7	0	0		
Metamyelocytes, Increase to high, n=1, 7	1	7		
Monocytes, Decrease to low, n=86, 43	3	20		
Monocytes, CTN or no change, n=86, 43	78	18		
Monocytes, Increase to high, n=86, 43	5	9		
Myelocytes, Decrease to low, n=1, 9	0	0		
Myelocytes, CTN or no change, n=1, 9	0	1		
Myelocytes, Increase to high, n=1, 9	1	8		
Neutrophil Bands (%), Decrease to low, n=1, 4	0	0		
Neutrophil Bands (%), CTN or no change, n=1, 4	1	3		
Neutrophil Bands (%), Increase to high, n=1, 4	0	1		

Notes:

[17] - Safety Population. Only participants with data available at the specified time points were analyzed.

[18] - Safety Population. Only participants with data available at the specified time points were analyzed.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with the indicated worst-case on-therapy change from Baseline with respect to normal ranges in the indicated hematology parameters: Crossover Phase

End point title	Number of participants with the indicated worst-case on-therapy change from Baseline with respect to normal ranges in the indicated hematology parameters: Crossover Phase
-----------------	--

End point description:

Data are presented for only those hematology parameters for which the following worst-case on-therapy changes from Baseline with respect to the normal range were observed: decrease to low, change to normal (CTN) or no change, or increase to high. Hematology parameters included: atypical lymphs, atypical lymphs (percentage [%]), basophils, eosinophils, metamyelocytes, monocytes, and myelocytes. Worst-case on-therapy changes from Baseline were summarized. Worst-case on-therapy was defined using the on-therapy window and changes were identified using both scheduled and unscheduled assessments. Normal ranges for each parameter may vary depending on the laboratory (central versus local) and the participant (age, gender, etc.).

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; Days 1, 8, and 15 of Cycle 1; and Day 1 of every cycle thereafter until treatment discontinuation of the Crossover Phase (up to Study Week 19)

<b>End point values</b>	GSK1120212 2 mg in CP	Docetaxel 75 mg/m <sup>2</sup> in CP		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	23 <sup>[19]</sup>	1 <sup>[20]</sup>		
Units: Participants				
Atypical lymphs, Decrease to low, n=3, 1	0	0		

Atypical lymphs, CTN or no change, n=3, 1	1	0		
Atypical lymphs, Increase to high, n=3, 1	2	1		
Atypical lymphs (%), Decrease to low, n=3, 1	0	0		
Atypical lymphs (%), CTN or no change, n=3, 1	1	0		
Atypical lymphs (%), Increase to high, n=3, 1	2	1		
Basophils, Decrease to low, n=23, 1	0	0		
Basophils, CTN or no change, n=23, 1	23	1		
Basophils, Increase to high, n=23, 1	0	0		
Eosinophils, Decrease to low, n=23, 1	0	0		
Eosinophils, CTN or no change, n=23, 1	23	1		
Eosinophils, Increase to high, n=23, 1	0	0		
Metamyelocytes, Decrease to low, n=1, 1	0	0		
Metamyelocytes, CTN or no change, n=1, 1	0	0		
Metamyelocytes, Increase to high, n=1, 1	1	1		
Monocytes, Decrease to low, n=23, 1	1	0		
Monocytes, CTN or no change, n=23, 1	20	0		
Monocytes, Increase to high, n=23, 1	2	1		
Myelocytes, Decrease to low, n=3, 1	0	0		
Myelocytes, CTN or no change, n=3, 1	0	0		
Myelocytes, Increase to high, n=3, 1	3	1		

Notes:

[19] - Crossover Population. Only par. with data available at the specified time points were analyzed.

[20] - Crossover Population. Only par. with data available at the specified time points were analyzed.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with any serious adverse event (SAE) or non-serious adverse event (AE): Randomized Phase

End point title	Number of participants with any serious adverse event (SAE) or non-serious adverse event (AE): Randomized Phase
-----------------	---

End point description:

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Medical or scientific judgment should have been exercised in deciding whether reporting was appropriate in other situations. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until 30 days following discontinuation of study treatment regardless of initiation of a new cancer therapy or transfer to hospice (maximum of 19 months)

End point values	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 <sup>[21]</sup>	43 <sup>[22]</sup>		
Units: Participants				
Any AE	87	43		
Any SAE	32	9		

Notes:

[21] - Safety Population

[22] - Safety Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with any SAE or non-serious AE: Crossover Phase

End point title	Number of participants with any SAE or non-serious AE: Crossover Phase
-----------------	--

End point description:

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. Medical or scientific judgment should have been exercised in deciding whether reporting was appropriate in other situations. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.

End point type	Secondary
----------------	-----------

End point timeframe:

From the date of the first dose of study treatment in the Crossover Phase until 30 days following discontinuation of study treatment regardless of initiation of a new cancer therapy or transfer to hospice (maximum of 12 months)

End point values	GSK1120212 2 mg in CP	Docetaxel 75 mg/m <sup>2</sup> in CP		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	23 <sup>[23]</sup>	2 <sup>[24]</sup>		
Units: Participants				
Any AE	22	2		
Any SAE	12	1		

Notes:

[23] - Crossover Population

[24] - Crossover Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Randomized Phase

End point title	Change from Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP): Randomized Phase
-----------------	--

**End point description:**

Systolic and diastolic blood pressure were measured at the following scheduled time points: Baseline; Days 1, 8, and 15 of Cycle 1 (Study Week 1); and Day 1 of every cycle thereafter until treatment discontinuation. The worst-case on-therapy was determined using both scheduled and unscheduled assessments during the on-therapy period. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Baseline; Days 1, 8, and 15 of Cycle 1; and Day 1 of every cycle thereafter until treatment discontinuation of the Randomized Phase (up to Study Week 40)

End point values	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 <sup>[25]</sup>	43 <sup>[26]</sup>		
Units: millimeters of mercury (mmHg)				
arithmetic mean (standard deviation)				
SBP, Worst-case on-therapy	13.5 (± 16.63)	3.1 (± 13.71)		
DBP, Worst-case on-therapy	10.7 (± 9.95)	2.5 (± 7.34)		

**Notes:**

[25] - Safety Population. Only participants with data available at the specified time points were analyzed.

[26] - Safety Population. Only participants with data available at the specified time points were analyzed.

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Change from Baseline in SBP and DBP: Crossover Phase**

End point title	Change from Baseline in SBP and DBP: Crossover Phase
-----------------	--

**End point description:**

Systolic and diastolic blood pressure were measured at the following scheduled time points: Baseline; Days 1, 8, and 15 of Cycle 1 (Study Week 1); and Day 1 of every cycle thereafter until treatment discontinuation. The worst-case on-therapy was determined using both scheduled and unscheduled assessments during the on-therapy period. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline. The standard deviation could not be calculated since only one participant was analyzed in this treatment arm at this time point; therefore, 99999 was entered which represents NA.

End point type	Secondary
----------------	-----------

**End point timeframe:**

Baseline; Days 1, 8, and 15 of Cycle 1; and Day 1 of every cycle thereafter until treatment discontinuation of the Crossover Phase (up to Study Week 19)

End point values	GSK1120212 2 mg in CP	Docetaxel 75 mg/m <sup>2</sup> in CP		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	23 <sup>[27]</sup>	1 <sup>[28]</sup>		
Units: mmHg				
arithmetic mean (standard deviation)				
SBP, Worst-case on-therapy	8.7 (± 15.95)	-15 (± 99999)		

DBP, Worst-case on-therapy	8.3 ( $\pm$ 12.28)	-12 ( $\pm$ 99999)		
----------------------------	--------------------	--------------------	--	--

Notes:

[27] - Crossover Population. Only par. with data available at the specified time points were analyzed.

[28] - Crossover Population. Only par. with data available at the specified time points were analyzed.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in heart rate: Randomized Phase

End point title	Change from Baseline in heart rate: Randomized Phase
-----------------	--

End point description:

Heart rate was measured at the following scheduled time points: Baseline; Days 1, 8, and 15 of Cycle 1 (Study Week 1); and Day 1 of every cycle thereafter until treatment discontinuation. The worst-case on-therapy was determined using both scheduled and unscheduled assessments during the on-therapy period. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; Days 1, 8, and 15 of Cycle 1; and Day 1 of every cycle thereafter until treatment discontinuation of the Randomized Phase (up to Study Week 40)

End point values	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	87 <sup>[29]</sup>	43 <sup>[30]</sup>		
Units: Beats per minute				
arithmetic mean (standard deviation)	10.4 ( $\pm$ 14.23)	13.2 ( $\pm$ 9.31)		

Notes:

[29] - Safety Population. Only participants with data available at the specified time points were analyzed.

[30] - Safety Population. Only participants with data available at the specified time points were analyzed.

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change from Baseline in heart rate: Crossover Phase

End point title	Change from Baseline in heart rate: Crossover Phase
-----------------	---

End point description:

Heart rate was measured at the following scheduled time points: Baseline; Days 1, 8, and 15 of Cycle 1 (Study Week 1); and Day 1 of every cycle thereafter until treatment discontinuation. The worst-case on-therapy was determined using both scheduled and unscheduled assessments during the on-therapy period. Change from Baseline was calculated as the value at post-Baseline time point minus the value at Baseline. The standard deviation could not be calculated since only one participant was analyzed in this treatment arm at this time point; therefore, 99999 was entered which represents NA.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline; Days 1, 8, and 15 of Cycle 1; and Day 1 of every cycle thereafter until treatment discontinuation of the Crossover Phase (up to Study Week 19)

End point values	GSK1120212 2 mg in CP	Docetaxel 75 mg/m <sup>2</sup> in CP		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	23 <sup>[31]</sup>	1 <sup>[32]</sup>		
Units: Beats per minute				
arithmetic mean (standard deviation)	8.5 (± 11.46)	5 (± 99999)		

Notes:

[31] - Crossover Population. Only par. with data available at the specified time points were analyzed.

[32] - Crossover Population. Only par. with data available at the specified time points were analyzed.

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with a best response of either a complete response (CR) or partial response (PR) as assessed by the investigator: Randomized Phase

End point title	Number of participants with a best response of either a complete response (CR) or partial response (PR) as assessed by the investigator: Randomized Phase
-----------------	---

End point description:

Response was assessed by the investigator according to RECIST, version 1.1, using confirmed and unconfirmed responses. Responders were defined as participants achieving either a CR (disappearance of all target and non-target lesions; any pathological lymph nodes must be <10 millimeters [mm] in the short axis; without the appearance of new lesions) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing response were treated as non-responders.

End point type	Secondary
----------------	-----------

End point timeframe:

From randomization until the first documented evidence of a CR or PR (maximum of 10.2 months)

End point values	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	86 <sup>[33]</sup>	43 <sup>[34]</sup>		
Units: Participants				
CR	0	0		
PR	10	5		

Notes:

[33] - MITT Population

[34] - MITT Population

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with a best response of either a CR or PR as assessed by the investigator: Crossover Phase

End point title	Number of participants with a best response of either a CR or
-----------------	---

**End point description:**

Response was assessed by the investigator according to RECIST, version 1.1, using confirmed and unconfirmed responses. Responders were defined as participants achieving either a CR (disappearance of all target and non-target lesions; any pathological lymph nodes must be <10 millimeters [mm] in the short axis; without the appearance of new lesions) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing response were treated as non-responders.

End point type	Secondary
----------------	-----------

**End point timeframe:**

From the date of the first dose of study treatment in the Crossover Phase until the first documented evidence of a CR or PR (maximum of 4 months)

End point values	GSK1120212 2 mg in CP	Docetaxel 75 mg/m <sup>2</sup> in CP		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	23 <sup>[35]</sup>	2 <sup>[36]</sup>		
Units: Participants				
CR	0	0		
PR	1	0		

**Notes:**

[35] - Crossover Population

[36] - Crossover Population

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Duration of response (DOR) as assessed by the investigator: Randomized Phase**

End point title	Duration of response (DOR) as assessed by the investigator: Randomized Phase
-----------------	--

**End point description:**

DOR was assessed by the investigator for par. with CR (disappearance of all target and non-target lesions; any pathological lymph nodes must be <10 mm in the short axis; without the appearance of new lesions) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). DOR is defined as the time from the first documented evidence of CR or PR until the earliest date of documented radiological progression or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters (SD) of target lesions with an absolute increase of at least 5 millimeters (mm) or the appearance of at least 1 new lesion, or the worsening of non-target lesions significant enough to require study treatment discontinuation. There were a limited number of par. with a CR or PR who progressed or died; therefore, the upper limit (UL) of the CI could not be estimated (99999=NA).

End point type	Secondary
----------------	-----------

**End point timeframe:**

Time from the first documented evidence of CR or PR until the earliest date of documented radiological progression or death due to any cause (maximum of 10.2 months)

End point values	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	10 <sup>[37]</sup>	5 <sup>[38]</sup>		
Units: Weeks				
arithmetic mean (confidence interval 95%)	6.7 (2.7 to 99999)	12.4 (7.1 to 17.3)		

Notes:

[37] - MITT Population. Only participants who achieved a CR or PR were analyzed for duration of response.

[38] - MITT Population. Only participants who achieved a CR or PR were analyzed for duration of response.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

OS is defined as the interval of time between the date of randomization and the date of death due to any cause. For participants who did not die, OS was censored at the date of last contact. Statistics for the median is missing because an insufficient number of participants reached the milestone, making calculation of this statistic inappropriate or impossible (99999=NA).

End point type	Secondary
----------------	-----------

End point timeframe:

Time interval between the date of randomization and the date of death due to any cause (maximum of 22 months)

End point values	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	86 <sup>[39]</sup>	43 <sup>[40]</sup>		
Units: Months				
median (confidence interval 95%)	8.1 (6.8 to 10)	9.9 (5 to 99999)		

Notes:

[39] - MITT Population

[40] - MITT Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: GSK1120212 plasma pharmacokinetic (PK) concentration

End point title	GSK1120212 plasma pharmacokinetic (PK) concentration
-----------------	--

End point description:

Blood samples for PK analysis of GSK1120212 were collected at the following time points: Cycle 1 (Study Day 15), Cycle 2 (Study Day 22), Cycle 3 (Study Day 43), and Cycle 4 (Study Day 64). Post-dose PK samples collected on Day 15 of Cycle 1 occurred at least 1 hour apart. Participants were instructed to withhold the dose of GSK1120212 until after blood for PK samples had been drawn. Pre-dose samples were taken 15 minutes or less prior to taking the next dose (i.e., trough).

End point type	Secondary
----------------	-----------



End point timeframe:

Day 15 of Cycle 1: pre-dose; 0.5-2 hours, 2-4 hours, and 4-8 hours post-dose; Day 1 of Cycle 2, Cycle 3 and Cycle 4: pre-dose

End point values	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	80 <sup>[41]</sup>	0 <sup>[42]</sup>		
Units: Nanograms (ng)/milliliter (mL)				
arithmetic mean (standard deviation)				
Cycle 1, Day 15, pre-dose, n=80	16.1 (± 5.31)	( )		
Cycle 1, Day 15, 0.5-2 hours post-dose, n=78	21.5 (± 8.59)	( )		
Cycle 1, Day 15, 2-4 hours post-dose, n=77	29.7 (± 22.9)	( )		
Cycle 1, Day 15, 4-8 hours post-dose, n=78	24.8 (± 7.8)	( )		
Cycle 2, Day 1, pre-dose, n=75	16.7 (± 6.95)	( )		
Cycle 3, Day 1, pre-dose, n=60	12.9 (± 7.19)	( )		
Cycle 4, Day 1, pre-dose, n=38	13.9 (± 6.49)	( )		

Notes:

[41] - PK Population. Only participants with data available at the specified time points were analyzed.

[42] - PK Population. Only participants with data available at the specified time points were analyzed.

## Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Serious Adverse Events (SAEs) and non-serious AEs were collected from the first dose of study treatment until 30 days following discontinuation of study treatment regardless of initiation of a new cancer therapy (maximum of 19 months).

Adverse event reporting additional description:

SAEs and non-serious AEs were collected in members of the Safety Population (all participants who received at least one dose of study treatment) and the Crossover Population (participants who, at the point of disease progression during the Randomized Phase, elected to enter the crossover portion of the study).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	15.1

### Reporting groups

Reporting group title	GSK1120212 2 mg in RP
-----------------------	-----------------------

Reporting group description:

Participants received GSK1120212 2 milligrams (mg) orally once daily continuously in the Randomized Phase (RP). Participants continued treatment until disease progression, death, or unacceptable adverse events were experienced. Participants who experienced disease progression in the RP were given the option of crossing over to the alternative treatment arm (docetaxel 75 milligrams per meters squared [ $\text{mg}/\text{m}^2$ ]), and continuing in the Cross-over Phase (CP).

Reporting group title	Docetaxel 75 $\text{mg}/\text{m}^2$ in RP
-----------------------	---

Reporting group description:

Participants received docetaxel 75 mg per meters squared ( $\text{m}^2$ ) intravenously (IV) every 3 weeks in the RP. Participants continued treatment on a 21-day cycle until disease progression, death, or unacceptable adverse events were experienced. Participants who experienced disease progression in the RP were given the option of crossing over to the alternative treatment arm (GSK1120212 2 mg), and continuing in the CP.

Reporting group title	GSK1120212 2 mg in CP
-----------------------	-----------------------

Reporting group description:

Participants who experienced disease progression in the RP were given the option of crossing over to GSK1120212 2 mg and continuing in the Cross-over Phase (CP).

Reporting group title	Docetaxel 75 $\text{mg}/\text{m}^2$ in CP
-----------------------	---

Reporting group description:

Participants who experienced disease progression in the RP were given the option of crossing over to docetaxel 75  $\text{mg}/\text{m}^2$  and continuing in the CP.

Serious adverse events	GSK1120212 2 mg in RP	Docetaxel 75 $\text{mg}/\text{m}^2$ in RP	GSK1120212 2 mg in CP
Total subjects affected by serious adverse events			
subjects affected / exposed	32 / 87 (36.78%)	9 / 43 (20.93%)	12 / 23 (52.17%)
number of deaths (all causes)	4	0	1
number of deaths resulting from adverse events	1	0	1
Vascular disorders			
Thrombosis			

subjects affected / exposed	2 / 87 (2.30%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	3 / 87 (3.45%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema			
subjects affected / exposed	2 / 87 (2.30%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	2 / 23 (8.70%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	2 / 87 (2.30%)	1 / 43 (2.33%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pulmonary embolism			
subjects affected / exposed	2 / 87 (2.30%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Bronchospasm			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary hypertension			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Hepatic enzyme increased subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Radiation pneumonitis subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pubis fracture subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Transient ischaemic attack subjects affected / exposed	2 / 87 (2.30%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Loss of consciousness			

subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Somnolence			
subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	0 / 87 (0.00%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	0 / 87 (0.00%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	2 / 87 (2.30%)	1 / 43 (2.33%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	2 / 2	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	2 / 87 (2.30%)	1 / 43 (2.33%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	2 / 2	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	1 / 87 (1.15%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 87 (0.00%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer perforation			

subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sigmoiditis			
subjects affected / exposed	0 / 87 (0.00%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	2 / 87 (2.30%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	4 / 4	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dermatitis exfoliative			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash generalised			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angioedema			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			

Renal failure acute			
subjects affected / exposed	2 / 87 (2.30%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Musculoskeletal pain			
subjects affected / exposed	0 / 87 (0.00%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			
subjects affected / exposed	0 / 87 (0.00%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	6 / 87 (6.90%)	1 / 43 (2.33%)	2 / 23 (8.70%)
occurrences causally related to treatment / all	0 / 6	1 / 1	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	4 / 87 (4.60%)	1 / 43 (2.33%)	2 / 23 (8.70%)
occurrences causally related to treatment / all	1 / 4	1 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jiroveci infection			
subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Bronchitis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis bacterial			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 87 (0.00%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash pustular			
subjects affected / exposed	0 / 87 (0.00%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	2 / 87 (2.30%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoalbuminaemia			
subjects affected / exposed	1 / 87 (1.15%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Docetaxel 75 mg/m <sup>2</sup> in CP		
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 2 (50.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Vascular disorders			
Thrombosis			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Embolism			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Venous thrombosis			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oedema			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Death			

subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General physical health deterioration			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute respiratory failure			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchospasm			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemoptysis			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary hypertension			

subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pleural effusion			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Hepatic enzyme increased			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Radiation pneumonitis			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Spinal compression fracture			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pubis fracture			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Nervous system disorders			
Transient ischaemic attack			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemic stroke			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Loss of consciousness			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Somnolence			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	1 / 2 (50.00%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vomiting			

subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastric ulcer perforation			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sigmoiditis			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Rash			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dermatitis exfoliative			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Palmar-plantar erythrodysesthesia syndrome			

subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rash generalised			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Angioedema			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal failure acute			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Musculoskeletal pain			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain in extremity			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Sepsis				
subjects affected / exposed	0 / 2 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumocystis jiroveci infection				
subjects affected / exposed	0 / 2 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Septic shock				
subjects affected / exposed	0 / 2 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchitis				
subjects affected / exposed	0 / 2 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchitis bacterial				
subjects affected / exposed	0 / 2 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	0 / 2 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
subjects affected / exposed	0 / 2 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung infection				
subjects affected / exposed	0 / 2 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rash pustular				



subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoalbuminaemia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	GSK1120212 2 mg in RP	Docetaxel 75 mg/m <sup>2</sup> in RP	GSK1120212 2 mg in CP
Total subjects affected by non-serious adverse events			
subjects affected / exposed	87 / 87 (100.00%)	43 / 43 (100.00%)	20 / 23 (86.96%)
Vascular disorders			
Hypertension			
subjects affected / exposed	30 / 87 (34.48%)	8 / 43 (18.60%)	2 / 23 (8.70%)
occurrences (all)	36	9	2
Hypotension			
subjects affected / exposed	9 / 87 (10.34%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences (all)	9	0	0
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	24 / 87 (27.59%)	12 / 43 (27.91%)	0 / 23 (0.00%)
occurrences (all)	27	16	0
Asthenia			

subjects affected / exposed	20 / 87 (22.99%)	11 / 43 (25.58%)	4 / 23 (17.39%)
occurrences (all)	23	15	4
Oedema peripheral			
subjects affected / exposed	19 / 87 (21.84%)	5 / 43 (11.63%)	7 / 23 (30.43%)
occurrences (all)	24	5	9
Pyrexia			
subjects affected / exposed	15 / 87 (17.24%)	4 / 43 (9.30%)	3 / 23 (13.04%)
occurrences (all)	20	5	6
Mucosal inflammation			
subjects affected / exposed	6 / 87 (6.90%)	6 / 43 (13.95%)	0 / 23 (0.00%)
occurrences (all)	10	7	0
Face oedema			
subjects affected / exposed	6 / 87 (6.90%)	2 / 43 (4.65%)	0 / 23 (0.00%)
occurrences (all)	6	2	0
Oedema			
subjects affected / exposed	6 / 87 (6.90%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences (all)	6	1	0
Chills			
subjects affected / exposed	6 / 87 (6.90%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences (all)	6	0	0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	28 / 87 (32.18%)	8 / 43 (18.60%)	4 / 23 (17.39%)
occurrences (all)	28	9	4
Cough			
subjects affected / exposed	24 / 87 (27.59%)	8 / 43 (18.60%)	6 / 23 (26.09%)
occurrences (all)	26	8	8
Haemoptysis			
subjects affected / exposed	7 / 87 (8.05%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences (all)	8	1	0
Oropharyngeal pain			
subjects affected / exposed	3 / 87 (3.45%)	5 / 43 (11.63%)	0 / 23 (0.00%)
occurrences (all)	3	5	0
Productive cough			

subjects affected / exposed	2 / 87 (2.30%)	5 / 43 (11.63%)	0 / 23 (0.00%)
occurrences (all)	3	5	0
Epistaxis			
subjects affected / exposed	0 / 87 (0.00%)	6 / 43 (13.95%)	2 / 23 (8.70%)
occurrences (all)	0	6	2
Pleural effusion			
subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	2 / 23 (8.70%)
occurrences (all)	0	0	2
Dyspnoea exertional			
subjects affected / exposed	0 / 87 (0.00%)	3 / 43 (6.98%)	0 / 23 (0.00%)
occurrences (all)	0	3	0
Pulmonary embolism			
subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	6 / 87 (6.90%)	9 / 43 (20.93%)	0 / 23 (0.00%)
occurrences (all)	6	9	0
Confusional state			
subjects affected / exposed	5 / 87 (5.75%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences (all)	5	0	0
Anxiety			
subjects affected / exposed	3 / 87 (3.45%)	3 / 43 (6.98%)	1 / 23 (4.35%)
occurrences (all)	3	3	1
Investigations			
Weight decreased			
subjects affected / exposed	9 / 87 (10.34%)	2 / 43 (4.65%)	0 / 23 (0.00%)
occurrences (all)	9	2	0
Aspartate aminotransferase increased			
subjects affected / exposed	6 / 87 (6.90%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences (all)	7	1	0
Neutrophil count decreased			
subjects affected / exposed	0 / 87 (0.00%)	7 / 43 (16.28%)	0 / 23 (0.00%)
occurrences (all)	0	8	0
Alanine aminotransferase increased			

subjects affected / exposed occurrences (all)	3 / 87 (3.45%) 4	3 / 43 (6.98%) 3	0 / 23 (0.00%) 0
Ejection fraction decreased subjects affected / exposed occurrences (all)	5 / 87 (5.75%) 6	0 / 43 (0.00%) 0	0 / 23 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	3 / 43 (6.98%) 3	0 / 23 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	6 / 87 (6.90%) 6	5 / 43 (11.63%) 7	2 / 23 (8.70%) 2
Neuropathy peripheral subjects affected / exposed occurrences (all)	2 / 87 (2.30%) 2	9 / 43 (20.93%) 10	0 / 23 (0.00%) 0
Dysgeusia subjects affected / exposed occurrences (all)	3 / 87 (3.45%) 3	5 / 43 (11.63%) 5	0 / 23 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	1 / 87 (1.15%) 1	3 / 43 (6.98%) 4	0 / 23 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	5 / 87 (5.75%) 5	2 / 43 (4.65%) 2	0 / 23 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	18 / 87 (20.69%) 18	8 / 43 (18.60%) 11	5 / 23 (21.74%) 6
Neutropenia subjects affected / exposed occurrences (all)	1 / 87 (1.15%) 2	15 / 43 (34.88%) 16	0 / 23 (0.00%) 0
Leukopenia subjects affected / exposed occurrences (all)	1 / 87 (1.15%) 1	5 / 43 (11.63%) 5	0 / 23 (0.00%) 0
Eye disorders			

Lacrimation increased subjects affected / exposed occurrences (all)	3 / 87 (3.45%) 3	3 / 43 (6.98%) 3	0 / 23 (0.00%) 0
Gastrointestinal disorders			
Diarrhoea subjects affected / exposed occurrences (all)	44 / 87 (50.57%) 60	9 / 43 (20.93%) 12	11 / 23 (47.83%) 20
Nausea subjects affected / exposed occurrences (all)	30 / 87 (34.48%) 37	12 / 43 (27.91%) 18	5 / 23 (21.74%) 8
Constipation subjects affected / exposed occurrences (all)	18 / 87 (20.69%) 21	8 / 43 (18.60%) 11	5 / 23 (21.74%) 6
Vomiting subjects affected / exposed occurrences (all)	20 / 87 (22.99%) 27	6 / 43 (13.95%) 7	5 / 23 (21.74%) 5
Dry mouth subjects affected / exposed occurrences (all)	13 / 87 (14.94%) 14	1 / 43 (2.33%) 1	3 / 23 (13.04%) 3
Abdominal pain upper subjects affected / exposed occurrences (all)	9 / 87 (10.34%) 12	2 / 43 (4.65%) 2	0 / 23 (0.00%) 0
Stomatitis subjects affected / exposed occurrences (all)	8 / 87 (9.20%) 8	3 / 43 (6.98%) 3	0 / 23 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	5 / 87 (5.75%) 7	3 / 43 (6.98%) 3	1 / 23 (4.35%) 1
Gastritis subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 43 (0.00%) 0	1 / 23 (4.35%) 1
Skin and subcutaneous tissue disorders			
Rash subjects affected / exposed occurrences (all)	51 / 87 (58.62%) 90	6 / 43 (13.95%) 6	7 / 23 (30.43%) 9
Alopecia			

subjects affected / exposed	2 / 87 (2.30%)	17 / 43 (39.53%)	0 / 23 (0.00%)
occurrences (all)	2	17	0
Pruritus			
subjects affected / exposed	17 / 87 (19.54%)	2 / 43 (4.65%)	0 / 23 (0.00%)
occurrences (all)	20	7	0
Dry skin			
subjects affected / exposed	15 / 87 (17.24%)	2 / 43 (4.65%)	3 / 23 (13.04%)
occurrences (all)	15	2	3
Dermatitis acneiform			
subjects affected / exposed	11 / 87 (12.64%)	2 / 43 (4.65%)	2 / 23 (8.70%)
occurrences (all)	11	2	3
Skin fissures			
subjects affected / exposed	8 / 87 (9.20%)	0 / 43 (0.00%)	0 / 23 (0.00%)
occurrences (all)	11	0	0
Nail disorder			
subjects affected / exposed	2 / 87 (2.30%)	3 / 43 (6.98%)	0 / 23 (0.00%)
occurrences (all)	2	3	0
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	6 / 87 (6.90%)	10 / 43 (23.26%)	0 / 23 (0.00%)
occurrences (all)	6	19	0
Back pain			
subjects affected / exposed	9 / 87 (10.34%)	6 / 43 (13.95%)	2 / 23 (8.70%)
occurrences (all)	9	7	2
Arthralgia			
subjects affected / exposed	3 / 87 (3.45%)	5 / 43 (11.63%)	0 / 23 (0.00%)
occurrences (all)	4	7	0
Muscular weakness			
subjects affected / exposed	0 / 87 (0.00%)	0 / 43 (0.00%)	1 / 23 (4.35%)
occurrences (all)	0	0	1
Infections and infestations			
Paronychia			
subjects affected / exposed	7 / 87 (8.05%)	1 / 43 (2.33%)	0 / 23 (0.00%)
occurrences (all)	7	1	0
Lung infection			

subjects affected / exposed occurrences (all)	0 / 87 (0.00%) 0	0 / 43 (0.00%) 0	0 / 23 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	5 / 87 (5.75%) 6	2 / 43 (4.65%) 2	0 / 23 (0.00%) 0
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	21 / 87 (24.14%) 22	7 / 43 (16.28%) 8	5 / 23 (21.74%) 5
Hypoalbuminaemia subjects affected / exposed occurrences (all)	9 / 87 (10.34%) 9	1 / 43 (2.33%) 1	4 / 23 (17.39%) 5
Hyperglycaemia subjects affected / exposed occurrences (all)	5 / 87 (5.75%) 5	2 / 43 (4.65%) 2	0 / 23 (0.00%) 0
Dehydration subjects affected / exposed occurrences (all)	5 / 87 (5.75%) 5	1 / 43 (2.33%) 1	0 / 23 (0.00%) 0
Hypokalaemia subjects affected / exposed occurrences (all)	5 / 87 (5.75%) 6	1 / 43 (2.33%) 1	0 / 23 (0.00%) 0

<b>Non-serious adverse events</b>	Docetaxel 75 mg/m <sup>2</sup> in CP		
Total subjects affected by non-serious adverse events subjects affected / exposed	1 / 2 (50.00%)		
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0		
Hypotension subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0		
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0		

Asthenia			
subjects affected / exposed	1 / 2 (50.00%)		
occurrences (all)	1		
Oedema peripheral			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Pyrexia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Mucosal inflammation			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Face oedema			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Oedema			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Chills			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 2 (50.00%)		
occurrences (all)	1		
Cough			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Haemoptysis			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Productive cough			



subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Epistaxis			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Pleural effusion			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Dyspnoea exertional			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Pulmonary embolism			
subjects affected / exposed	1 / 2 (50.00%)		
occurrences (all)	1		
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Confusional state			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Anxiety			
subjects affected / exposed	1 / 2 (50.00%)		
occurrences (all)	1		
Investigations			
Weight decreased			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Neutrophil count decreased			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Alanine aminotransferase increased			

subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Ejection fraction decreased			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
White blood cell count decreased			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Neuropathy peripheral			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Dysgeusia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Paraesthesia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Leukopenia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Eye disorders			

Lacrimation increased subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0		
Gastrointestinal disorders			
Diarrhoea subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1		
Nausea subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0		
Constipation subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0		
Vomiting subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0		
Dry mouth subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0		
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0		
Stomatitis subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0		
Abdominal pain subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1		
Gastritis subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1		
Skin and subcutaneous tissue disorders			
Rash subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0		
Alopecia			

subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Dry skin			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Dermatitis acneiform			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Skin fissures			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Nail disorder			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Myalgia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Back pain			
subjects affected / exposed	1 / 2 (50.00%)		
occurrences (all)	1		
Arthralgia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Muscular weakness			
subjects affected / exposed	1 / 2 (50.00%)		
occurrences (all)	2		
Infections and infestations			
Paronychia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Lung infection			

subjects affected / exposed	1 / 2 (50.00%)		
occurrences (all)	1		
Urinary tract infection			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Hypoalbuminaemia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Hyperglycaemia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Dehydration			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	0 / 2 (0.00%)		
occurrences (all)	0		

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 October 2012	The protocol was amended to consider the recommendation of the independent Safety Review Committee following their review of the results of the pre-specified interim analysis of efficacy and safety. Following the iSRC findings from the pre-planned interim analysis, the GSK1120212 arm was modified. All subjects currently receiving GSK1120212 were permanently discontinued from GSK1120212 (except in subjects deriving clinical benefit without severe drug-induced toxicity). The option to crossover to the alternate treatment arm at disease progression was no longer allowed. The study was considered complete when 50% of subjects with KRAS mutant positive disease have died.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported